JATT III Acquisition Corp closed a $69 million initial public offering on the Nasdaq Global Market. The company issued 6,900,000 ordinary shares at $10 per share, including 900,000 shares exercised under the underwriters' over‑allotment option. Gross proceeds are reported before underwriting discounts, commissions and other expenses.
The registration statement was declared effective by the U.S. Securities and Exchange Commission on Aug 25, 2026. Trading of the shares began on Aug 26, 2026, and the offering formally closed on Aug 27, 2026. The company trades under the ticker symbol JTTT.
JATT III Acquisition Corp is a blank‑check vehicle incorporated in the Cayman Islands that intends to pursue a business combination in the healthcare sector, with a focus on biotechnology and life sciences. No specific target has been identified to date.
Guggenheim Securities acted as the sole book‑running manager for the offering. Institutional investors that participated include Adage Capital Partners, ADAR1 Capital, Affinity Asset Advisors, Columbia Threadneedle Investments, Deep Track Capital, Great Point Partners, Janus Henderson Investors, Nantahala Capital, RA Capital Management, Sirenia Capital Management, and Squadron Capital Management. In a parallel private placement, AI Biotechnology LLC – an affiliate of Access Industries – and Vianti Capital Fund I expressed non‑binding interest alongside the initial business combination.
